Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (17432)	1/1/2002 11:49:44 AM
From: Logain Ablar	Respond to of 99280

Happy New Year Zeev:

To: Zeev Hed who wrote (17432)	1/1/2002 12:32:44 PM
From: puborectalis	Respond to of 99280

Standard chemotherapy treatment of stage II and III colon cancer is defined and may prevent patients from having to receive unnecessarily prolonged or more toxic treatments. (Proceedings American Society of Clinical Oncology, Volume 17, Abstract 982, 1998) Adjuvant treatment of colon cancer with 5-fluouracil and various doses of leucovorin and Ergamisol® (levamisole) have all been considered standard treatment options because they prolong the recurrence-free and overall survival of patients compared to no additional treatment. In order to determine if one treatment regimen is superior, a randomized, comparative, controlled clinical study was performed evaluating the 4 most common 5-fluouracil -based chemotherapy combinations. In this clinical study, 3,759 patients with high-risk stage II and stage III colon cancer were treated with either 5-fluouracil and low-dose leucovorin, 5-fluouracil and high-dose leucovorin, or 5-fluouracil and low-dose leucovorin and Ergamisol® for 6 months and compared to the standard 12 month regimen of 5-fluouracil and Ergamisol®. Patients treated with 5-fluouracil and low-dose leucovorin achieved a 60% 5-year disease-free survival and a 66% overall survival rate. None of the other 3 treatment options exceeded the results achieved with 6 months of 5-fluouracil and low-dose leucovorin. These data suggest that 6 months of adjuvant chemotherapy with 5-fluouracil and low-dose leucovorin can be considered the current standard therapy for patients with stage II and III colon carcinoma. All the other regimens delivered higher doses of chemotherapy, which are more likely to be associated with increased side effects or require patients to receive a longer duration of treatment without additional benefit. (Proceedings American Society of Clinical Oncology, Volume 17, Abstract 982, 1998)..........................Also:......The 5-year overall survival rate for patients treated with monoclonal antibody is approximately 65% compared to 50% for patients treated with surgery alone....................(.not encouraging)